05 March 2018 | News
The BioPharmaSpec approach has the distinct advantage of detecting HCPs in a de novo manner, without specialized polyclonal antibody reagents or product / process-specific method development
US based BioPharmaSpec, a contract research organization (CRO) has announced the launch of “The BioPharmaSpec Approach” for MS-based detection of Host Cell Proteins (HCPs).
The new in-house service allows clients access to a pre-existing approach that detects a wider population of HCPs than possible with traditional ELISA technologies.
The BioPharmaSpec approach has the distinct advantage of detecting HCPs in a de novo manner, without specialized polyclonal antibody reagents or product / process-specific method development.
BioPharmaSpec apply their renowned MS expertise within a clearly-defined, staged approach, which includes Qualitative analysis to identify the HCPs present, Quantitation against a response from a known spiked protein and Quantitation of the HCPs against heavy labeled marker peptides.
Dr Andrew Reason, CEO at BioPharmaSpec commented: “Through our significant experience, high-end MS technologies and intuitive, specialized software, our clients have been progressively adopting MS as technique for analyzing HCPs in their products. In turn, this trend has swayed regulatory groups worldwide, who now often recommend the use of MS as an orthogonal approach to HCP-ELISA.”
“At BioPharmaSpec, we remain committed to positioning ourselves at the forefront of our industry, constantly looking for ways to innovate and bring the best technical service to our Clients. We look forward to serving our industry with The BioPharmaSpec Approach to HCP detection, and improving HCP assessments with the more decisive analytical technique of MS”, he added.